Aripiprazole: Dosing, Indications, and Safety
For schizophrenia in adults, start aripiprazole at 10-15 mg once daily and maintain this dose, as higher doses provide no additional benefit and the optimal therapeutic dose is 10 mg/day. 1
Approved Indications
Aripiprazole is FDA-approved for:
- Schizophrenia (adults and adolescents 13-17 years)
- Bipolar I disorder (acute manic episodes and maintenance)
- Irritability associated with autistic disorder (pediatric patients) 1, 2
Dosing Guidelines
Adults with Schizophrenia
Initial dosing: Start at 10 or 15 mg once daily without regard to meals 1
Dose range: While FDA-approved for 10-30 mg/day, doses above 10-15 mg/day show no superior efficacy 1. Research demonstrates the optimal dose is 10 mg/day with the highest response rate at this dose 3. Doses above 20 mg/day provide no additional benefit and may paradoxically result in smaller symptom improvements 3.
Titration: Do not increase doses before 2 weeks—this is the time required to reach steady-state concentrations 1, 4. Full therapeutic effect may take 1-4 weeks to manifest 4.
Adolescents (13-17 years) with Schizophrenia
Target dose: 10 mg/day 1
Titration schedule:
- Start: 2 mg daily
- Day 3: Increase to 5 mg
- Day 5: Increase to target 10 mg
- Subsequent increases: 5 mg increments if needed
The 30 mg/day dose showed no superiority over 10 mg/day in adolescent trials 1.
Dose Adjustments for Drug Interactions
Critical adjustments are required based on CYP450 metabolism 1:
| Clinical Scenario | Dose Adjustment |
|---|---|
| Known CYP2D6 poor metabolizers | Half usual dose |
| Strong CYP3A4 inhibitors (itraconazole, clarithromycin) OR strong CYP2D6 inhibitors (quinidine, fluoxetine, paroxetine) | Half usual dose |
| Both strong CYP3A4 AND CYP2D6 inhibitors | Quarter usual dose |
| CYP2D6 poor metabolizers + strong CYP3A4 inhibitors | Quarter usual dose |
| Strong CYP3A4 inducers (carbamazepine, rifampin) | Double usual dose over 1-2 weeks |
When the interacting drug is discontinued, return to original aripiprazole dose (reduce gradually over 1-2 weeks for inducers) 1.
Therapeutic Drug Monitoring
Therapeutic reference range: 120-270 ng/mL for aripiprazole alone, or 180-380 ng/mL for aripiprazole plus its active metabolite 5
This is particularly important given:
- High interindividual variability in metabolism
- CYP2D6 genetic polymorphisms significantly affect drug levels
- A 10 mg starting dose achieves effective concentrations in most patients; 5 mg is sufficient for known CYP2D6 poor metabolizers 5
Common Adverse Effects
Most common (≥10%) in adults: Nausea, vomiting, constipation, headache, dizziness, akathisia, anxiety, insomnia, restlessness 1
Most common (≥10%) in pediatrics: Somnolence, headache, vomiting, extrapyramidal disorder, fatigue, increased appetite, insomnia, nausea, weight gain 1
Notable: Akathisia is the only adverse effect occurring at twice the placebo rate (8% vs 4%) 1
Critical Safety Warnings
- Black box warning: Increased mortality in elderly patients with dementia-related psychosis 1
- Cerebrovascular adverse events including stroke
- Suicidal thoughts/behaviors in children, adolescents, and young adults
- Neuroleptic malignant syndrome
- Tardive dyskinesia
- Metabolic changes (though aripiprazole has favorable metabolic profile compared to other antipsychotics) 2
- Pathological gambling and compulsive behaviors
- Orthostatic hypotension and falls
- Leukopenia/neutropenia/agranulocytosis 1
Switching from Other Antipsychotics
Maintain the therapeutic dose of current antipsychotic while adding aripiprazole 15 mg/day (range 5-20 mg/day). Only after reaching an effective aripiprazole dose should you taper the previous medication 6. The overlap period should be minimized but gradual discontinuation may be appropriate for some patients 1.
Special Considerations for Treatment-Resistant Schizophrenia
Current guidelines support adjunctive low-dose aripiprazole for augmentation of clozapine or other antipsychotics, particularly for managing hyperprolactinemia 7. Aripiprazole's D2 partial agonist properties make it uniquely suited for this augmentation strategy.
Long-Acting Injectable Formulations
Two-month LAI formulations are now available (aripiprazole lauroxil 1064 mg and aripiprazole monohydrate 960 mg), offering extended dosing intervals while maintaining therapeutic plasma concentrations above 95 ng/mL 8, 9.